HRP950304B1 - Palladium catalyzed ring closure of triazolyl tryptamine - Google Patents

Palladium catalyzed ring closure of triazolyl tryptamine

Info

Publication number
HRP950304B1
HRP950304B1 HRP950304A HRP950304B1 HR P950304 B1 HRP950304 B1 HR P950304B1 HR P950304 A HRP950304 A HR P950304A HR P950304 B1 HRP950304 B1 HR P950304B1
Authority
HR
Croatia
Prior art keywords
ring closure
tryptamine
triazolyl
catalyzed ring
palladium catalyzed
Prior art date
Application number
Other languages
English (en)
Inventor
Cheng Y Chen
Robert D Larsen
Thomas R Verhoeven
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HRP950304A2 publication Critical patent/HRP950304A2/xx
Publication of HRP950304B1 publication Critical patent/HRP950304B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Inorganic Insulating Materials (AREA)
HR08/248,288 1994-05-24 1995-05-23 Palladium catalyzed ring closure of triazolyl tryptamine HRP950304B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/248,288 US5567824A (en) 1994-05-24 1994-05-24 Palladium catalyzed ring closure of triazolyltryptamine

Publications (2)

Publication Number Publication Date
HRP950304A2 HRP950304A2 (en) 1997-08-31
HRP950304B1 true HRP950304B1 (en) 2004-12-31

Family

ID=22938473

Family Applications (1)

Application Number Title Priority Date Filing Date
HR08/248,288 HRP950304B1 (en) 1994-05-24 1995-05-23 Palladium catalyzed ring closure of triazolyl tryptamine

Country Status (24)

Country Link
US (1) US5567824A (es)
EP (1) EP0763032B1 (es)
JP (1) JP3947216B2 (es)
KR (1) KR100385027B1 (es)
CN (2) CN1157390C (es)
AT (1) ATE252095T1 (es)
AU (1) AU688505B2 (es)
DE (1) DE69531939T2 (es)
DK (1) DK0763032T3 (es)
ES (1) ES2207648T3 (es)
FI (1) FI116899B (es)
HK (2) HK1009045A1 (es)
HR (1) HRP950304B1 (es)
HU (1) HU226460B1 (es)
MX (1) MX9605838A (es)
NZ (1) NZ285539A (es)
PT (1) PT763032E (es)
RO (1) RO118586B1 (es)
RU (1) RU2138496C1 (es)
SK (1) SK284495B6 (es)
TW (1) TW300221B (es)
UA (1) UA52586C2 (es)
WO (1) WO1995032197A1 (es)
YU (1) YU49345B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
DE69616335T2 (de) * 1995-07-11 2002-07-11 Merck & Co Inc Ein triazolylmethyl-indol-ethylamin-bisulfat-salz
US5811551A (en) * 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
US5808064A (en) * 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
US5877329A (en) * 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
ATE228137T1 (de) * 1996-08-13 2002-12-15 Merck & Co Inc Palladiumkatalysierte indolisierung
DE60033859T2 (de) * 1999-06-28 2007-11-08 Janssen Pharmaceutica N.V. Hemmer des Respiratorischen Syncytial Virus
ES2204303B2 (es) * 2002-08-07 2004-12-16 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
US7777049B2 (en) * 2004-01-09 2010-08-17 Ratiopharm Gmbh Crystalline forms of Rizatriptan benzoate
ATE461916T1 (de) * 2004-01-28 2010-04-15 Ratiopharm Gmbh Syntheseverfahren und zwischenprodukte zur herstellung von rizatriptan
GT200500065A (es) * 2004-03-26 2005-10-24 Procedimientos para la preparacion de compuestos aminoarilos yodados
WO2006082598A2 (en) * 2005-02-01 2006-08-10 Natco Pharma Limited Novel crystalline forms of rizatriptan benzoate
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
US20090062550A1 (en) * 2005-11-14 2009-03-05 Matrix Laboratories Ltd Process for the Large Scale Production of Rizatriptan Benzoate
WO2007083320A2 (en) * 2006-01-19 2007-07-26 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
WO2008149152A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
EP3407869A1 (en) 2016-01-27 2018-12-05 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
GB9215526D0 (en) * 1992-07-22 1992-09-02 Merck Sharp & Dohme Chemical process

Also Published As

Publication number Publication date
AU688505B2 (en) 1998-03-12
EP0763032A1 (en) 1997-03-19
ATE252095T1 (de) 2003-11-15
DE69531939T2 (de) 2004-07-29
DE69531939D1 (de) 2003-11-20
CN1077104C (zh) 2002-01-02
HK1009045A1 (en) 1999-05-21
HRP950304A2 (en) 1997-08-31
HU226460B1 (en) 2008-12-29
KR970703336A (ko) 1997-07-03
RO118586B1 (ro) 2003-07-30
RU2138496C1 (ru) 1999-09-27
UA52586C2 (uk) 2003-01-15
US5567824A (en) 1996-10-22
FI964669A0 (fi) 1996-11-22
CN1322725A (zh) 2001-11-21
CN1152920A (zh) 1997-06-25
ES2207648T3 (es) 2004-06-01
CN1157390C (zh) 2004-07-14
PT763032E (pt) 2004-02-27
FI964669A (fi) 1996-11-22
JP3947216B2 (ja) 2007-07-18
YU49345B (sh) 2005-07-19
HK1041262A1 (en) 2002-07-05
YU33495A (sh) 1998-07-10
FI116899B (fi) 2006-03-31
NZ285539A (en) 1998-06-26
AU2467195A (en) 1995-12-18
KR100385027B1 (ko) 2003-08-14
DK0763032T3 (da) 2004-02-09
HK1041262B (zh) 2005-04-15
HU9603236D0 (en) 1997-01-28
TW300221B (es) 1997-03-11
EP0763032B1 (en) 2003-10-15
JPH10500680A (ja) 1998-01-20
SK149896A3 (en) 1997-09-10
HUT76469A (en) 1997-09-29
SK284495B6 (sk) 2005-05-05
WO1995032197A1 (en) 1995-11-30
MX9605838A (es) 1997-12-31

Similar Documents

Publication Publication Date Title
HRP950304B1 (en) Palladium catalyzed ring closure of triazolyl tryptamine
EA200000393A1 (ru) Химические соединения
PT74626A (en) Process for preparing 9-<2-(3-indolyl)ethyl>-1-oxa-4,9-diazas- piro<5,5>undecan-3-ones
GB9412590D0 (en) Organic compounds
ATE48835T1 (de) Chinolylglycinamidderivate, verfahren zu ihrer herstellung und therapeutische verwendung als psychotrope.
GB9004301D0 (en) Indolebutyric acid derivatives and process for preparation thereof
YU217181A (en) Process for preparing 2-(1,4-benzodioxane-2-ylalkyl)-imidazoles
NO178030C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive metylenbisfosfonsyrederivater
KR840004746A (ko) 2-옥소-1-아제티딘술폰산 유도체의 제조방법
GB9306899D0 (en) Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
CA2190851A1 (en) Palladium catalyzed ring closure of triazolyl tryptamine
JPS5359663A (en) 2-halogeno methyl indole derivatives and process for praparation of the same
HUT59157A (en) Process for producing 4-amino-delta-4'6-steroids
ES2160909T3 (es) Procedimiento para la preparacion de 4-amino-1,2,4-triazoles.
GR3032427T3 (en) An improved process for preparing side chain derivatives of cyclohexapeptidyl lipopeptides
ES8407042A1 (es) Procedimiento para la obtencion de un nuevo derivado del sulpiride.
HU9302786D0 (en) New thiophene-2-carboxylic acid derivatives and process for preparing them
KR970042548A (ko) 이미다조 피리딘 유도체,이의 제조방법 및 이를 함유한 약제학적 조성물
GB9815481D0 (en) Pharmaceuticals
JPS5681559A (en) Novel hydrazone compound and its preparation
HUP0000144A2 (hu) Eljárás hidroxi-heteroaromás vegyületek aril-aminokká való átalakítására
RO116269B1 (ro) Procedeu de obţinere a silicatului de sodiu lichid
JPS5640677A (en) Catechol derivative and its preparation
JPS5566562A (en) Novel imidazole derivative and antidepressant containing the same

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

PNAN Change of the applicant name, address/residence

Owner name: SCHERING CORPORATION, US

Owner name: MERCK SHARP & DOHME CORP., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20140515

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20150523